Abbott Laboratories (NYSE: ABT) Could Be Viewed Differently By Investors Because Of These Numbers

After Hours

The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Stocks Info

The company is listed on the NYSE and operates within the Medical Devices industry segment. The current market capitalization of Abbott Laboratories is $186.99B. A total of 8.49 million shares were traded on the day, compared to an average of 6.02M shares.

In the most recent transaction, Funck, Jr. Robert E. sold 10,097 shares of ABT for 104.57 per share on May 10 ’24. After the transaction, the EXECUTIVE VICE PRESIDENT now owns 211,341 company shares. In a previous transaction on May 07 ’24, Earnhardt Lisa D sold 22,852 shares at 106.25 per share. ABT shares that EXECUTIVE VICE PRESIDENT owns now total 61,462.

Among the insiders who sold shares, Salvadori Daniel Gesua Sive disposed of 963 shares on Mar 01 ’24 at a per-share price of $118.50. This resulted in the EXECUTIVE VICE PRESIDENT holding 125,697 shares of ABT after the transaction. In another insider transaction, ALLEN HUBERT L sold 853 shares at $118.50 per share on Mar 01 ’24. Company shares held by the EXECUTIVE VICE PRESIDENT now total 184,806.


The dividend paying company demonstrates a positive outlook for investors and helps them generate immediate cash. Abbott Laboratories pays an annual dividend of $2.12, resulting in a dividend yield of 1.97%, and it has a price to earnings (P/E) ratio of 33.48. ABT’s most recent ex-dividend date was 4/12/2024 when it declared a $0.55 quarterly dividend that was paid in cash on 5/15/2024. Previously, the company paid the dividend on 2/15/2024 with an ex-dividend date of 1/11/2024. The ABT stock dividend was $0.55 per share in cash.

It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. In terms of 52-week highs and lows, ABT has a high of $121.64 and a low of $89.67.

Balance Sheet Annually/Quarterly

An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information. ABT’s latest balance sheet shows that the firm has $10.25B in Cash & Short Term Investments as of fiscal 2021. There were $19.01B in debt and $13.11B in liabilities at the time. Its Book Value Per Share was $22.31, while its Total Shareholder’s Equity was $36.02B.

Analysts Opinion

There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for ABT is Buy with a score of 4.50.

Most Popular

Related Posts